Coya Therapeutics (COYA) News Today $6.10 -0.44 (-6.73%) Closing price 04:00 PM EasternExtended Trading$6.48 +0.39 (+6.31%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period AIGH Capital Management LLC Grows Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)AIGH Capital Management LLC lifted its position in Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) by 85.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,201,152 shares of the company's stock after buying an additionalMarch 31 at 6:58 AM | marketbeat.comCoya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral CapitalMarch 30, 2025 | americanbankingnews.comChardan Capital Has Strong Estimate for COYA FY2025 EarningsMarch 29, 2025 | americanbankingnews.comCoya Therapeutics (NASDAQ:COYA) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Thursday.March 28, 2025 | marketbeat.comChardan Capital Has Strong Forecast for COYA FY2025 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the company will post eaMarch 28, 2025 | marketbeat.comCoya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome ProgramMarch 26, 2025 | businesswire.comCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday.March 21, 2025 | marketbeat.comCoya Therapeutics Reports 2024 Financial Results and ProgressMarch 21, 2025 | tipranks.comCoya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth PlansMarch 20, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPSCoya Therapeutics (NASDAQ:COYA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14.March 19, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday.March 19, 2025 | marketbeat.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comCoya Therapeutics Reports 2024 Financial Results and UpdatesMarch 18, 2025 | tipranks.comCoya Therapeutics (COYA) to Release Earnings on TuesdayCoya Therapeutics (NASDAQ:COYA) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)D. Boral Capital reiterated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Monday.March 10, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Trading Up 4.5% - Should You Buy?Coya Therapeutics (NASDAQ:COYA) Stock Price Up 4.5% - Should You Buy?March 4, 2025 | marketbeat.comCoya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and CombinationsFebruary 26, 2025 | businesswire.comCoya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and CombinationsFebruary 25, 2025 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Biohaven Ltd. (BHVN) and Arvinas Holding Company (ARVN)February 12, 2025 | markets.businessinsider.com70,000 Shares in Coya Therapeutics, Inc. (NASDAQ:COYA) Bought by Newbridge Financial Services Group Inc.Newbridge Financial Services Group Inc. acquired a new stake in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 70,000 shares of the cFebruary 10, 2025 | marketbeat.comCoya Therapeutics Now Pivots Toward Phase 2 In ALS And FTDFebruary 7, 2025 | seekingalpha.comCoya: A Few Catalysts On The Way For COYA-302 Makes This A Must WatchFebruary 7, 2025 | seekingalpha.comCoya: Low-Dose IL-2 in AD patients resulted in reduced proinflammatory markersFebruary 7, 2025 | markets.businessinsider.comBTIG maintains Coya Therapeutics stock buy rating, $15 targetFebruary 6, 2025 | msn.comCoya reports promising Alzheimer's treatment study resultsFebruary 6, 2025 | msn.comCoya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly DosingFebruary 6, 2025 | benzinga.comD. Boral Capital Reaffirms "Buy" Rating for Coya Therapeutics (NASDAQ:COYA)D. Boral Capital restated a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Thursday.February 6, 2025 | marketbeat.comAn ALS treatment wave is approaching, and this biotech CEO is ready to surfJanuary 27, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Stock, Short Interest ReportJanuary 21, 2025 | benzinga.comCoya Therapeutics expands investigational pipeline, advancement of COYA 303January 21, 2025 | markets.businessinsider.comCoya Therapeutics advances COYA 303 for inflammatory diseasesJanuary 21, 2025 | msn.comEXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory DiseasesJanuary 21, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and set a $15.00 price objective on shares of Coya Therapeutics in a research note on Tuesday.January 21, 2025 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 10.2% in DecemberCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 209,200 shares, a growth of 10.2% from the December 15th total of 189,800 shares. Based on an average daily volume of 92,500 shares, the days-to-cover ratio is currently 2.3 days. Approximately 1.4% of the company's shares are short sold.January 19, 2025 | marketbeat.comDelveInsight Business Research, LLP: Exosome Therapies Market Poised for Explosive Growth During the Study Period (2025-2034) | DelveInsightJanuary 13, 2025 | finanznachrichten.deCoya Therapeutics, Inc. Common Stock (COYA) Institutional HoldingsDecember 23, 2024 | nasdaq.comD. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)D. Boral Capital reaffirmed a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday.December 18, 2024 | marketbeat.comD. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationDecember 5, 2024 | msn.comD. Boral Capital Initiates Coverage on Coya Therapeutics (NASDAQ:COYA)D. Boral Capital began coverage on Coya Therapeutics in a report on Wednesday. They issued a "buy" rating and a $15.00 target price on the stock.December 4, 2024 | marketbeat.comCoya: COYA 301 – GLP-1 agonists combo synergistic in inflamation ameliorationNovember 21, 2024 | markets.businessinsider.comCoya Therapeutics files to sell 1.38M shares of common stock for holdersNovember 21, 2024 | markets.businessinsider.comCoya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder Buys 1,800 SharesNovember 15, 2024 | insidertrades.comHC Wainwright Has Optimistic Outlook of COYA FY2024 EarningsCoya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Coya Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.13) per share forNovember 14, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Insider Fred Grossman Purchases 2,710 SharesNovember 13, 2024 | insidertrades.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday.November 11, 2024 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPSCoya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.15.November 9, 2024 | marketbeat.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial ResultsNovember 7, 2024 | finance.yahoo.comCoya Therapeutics Advances Pipeline for Neurodegenerative DiseasesNovember 7, 2024 | markets.businessinsider.comCoya Therapeutics Reports Q3 2024 Highlights and ProgressNovember 7, 2024 | markets.businessinsider.comCoya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday.November 7, 2024 | marketbeat.com Remove Ads Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address COYA Media Mentions By Week COYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.900.60▲Average Medical News Sentiment COYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼72▲COYA Articles Average Week Remove Ads Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zevra Therapeutics News Today REGENXBIO News Today Phathom Pharmaceuticals News Today SIGA Technologies News Today Erasca News Today Humacyte News Today SNDL News Today PureTech Health News Today Upstream Bio News Today Cartesian Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COYA Stock Free COYA Stock Alerts